Your browser is no longer supported. Please, upgrade your browser.
Settings
VLRX Valeritas Holdings, Inc. daily Stock Chart
VLRX [NASD]
Valeritas Holdings, Inc.
Index- P/E- EPS (ttm)-19.51 Insider Own0.41% Shs Outstand7.40M Perf Week-1.35%
Market Cap10.80M Forward P/E- EPS next Y-7.12 Insider Trans0.00% Shs Float6.13M Perf Month14.06%
Income-54.30M PEG- EPS next Q-2.52 Inst Own37.20% Short Float4.22% Perf Quarter-39.42%
Sales27.70M P/S0.39 EPS this Y80.90% Inst Trans13.67% Short Ratio1.06 Perf Half Y-73.92%
Book/sh-1.48 P/B- EPS next Y30.20% ROA-96.30% Target Price11.00 Perf Year-92.74%
Cash/sh3.69 P/C0.40 EPS next 5Y- ROE- 52W Range1.10 - 19.60 Perf YTD-77.57%
Dividend- P/FCF- EPS past 5Y- ROI-76.90% 52W High-92.55% Beta1.95
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin47.60% 52W Low32.73% ATR0.13
Employees82 Current Ratio2.60 Sales Q/Q15.40% Oper. Margin- RSI (14)49.44 Volatility10.87% 9.37%
OptionableNo Debt/Eq- EPS Q/Q78.10% Profit Margin- Rel Volume1.08 Prev Close1.50
ShortableYes LT Debt/Eq- EarningsNov 12 AMC Payout- Avg Volume244.71K Price1.46
Recom1.00 SMA202.85% SMA50-2.48% SMA200-65.04% Volume263,633 Change-2.67%
Jul-05-18Initiated Oppenheimer Outperform $3.50
Nov-13-19 08:06AM  Edited Transcript of VLRX earnings conference call or presentation 12-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
Nov-12-19 04:05PM  Valeritas Announces Third Quarter 2019 Financial Results GlobeNewswire
Oct-29-19 07:00AM  Valeritas Presents Positive h-Patch Apomorphine Study Data at the World Congress of Neurology (WCN 2019) GlobeNewswire +5.71%
Oct-24-19 07:00AM  Valeritas to Report Third Quarter 2019 Financial Results on November 12, 2019 GlobeNewswire
Oct-21-19 07:00AM  GLP-1 Analogue Delivered Robustly via Subcutaneous Infusion with Valeritas Proprietary h-Patch Wearable Device in Preclinical Study GlobeNewswire
Oct-15-19 07:00AM  Valeritas Presents Positive h-Patch Apomorphine Study Data at Global Experts Meeting on Frontiers in Alzheimers Disease & Dementia GlobeNewswire
Oct-10-19 07:00AM  Valeritas Announces Poster Presentation of Preclinical h-Patch Cannabidiol (CBD) Study at the American Epilepsy Society's Annual Meeting GlobeNewswire
Oct-08-19 07:00AM  Valeritas Announces Poster Presentation of Preclinical h-Patch Apomorphine Study at the World Congress of Neurology (WCN 2019) GlobeNewswire
Oct-03-19 07:00AM  Valeritas Hosts Educational Symposium and Participates in the Metabolic & Endocrine Disease Summit (MEDS) East GlobeNewswire
Oct-02-19 07:00AM  Valeritas Reduces its Long-Term Debt Obligation Nearly 60% by Exchanging $25.0 Million of Debt for Series B Convertible Preferred Stock GlobeNewswire +5.43%
Sep-30-19 09:58AM  Medtronic's All Business Lines Grow Despite Cost Concerns Zacks
08:59AM  Boston Scientific (BSX) Upbeat on Results of EVOLVE Study Zacks
Sep-27-19 10:08AM  Haemonetics Grows on Strong Plasma, Hemostasis Management Zacks
08:45AM  NuVasive Announces Innovations in Robotics Spine Surgery Line Zacks
Sep-26-19 09:31AM  Valeritas Announces Participation on The Cutting Edge of Cannabinoid Science Panel at the CBD Expo EAST Conference GlobeNewswire
Sep-24-19 07:00AM  Valeritas Presents Positive h-Patch CBD Study Data at CannMed Conference GlobeNewswire
Sep-19-19 07:00AM  Valeritas Announces Presentation of Preclinical h-Patch CBD Study at CannMed Conference GlobeNewswire
Sep-17-19 07:00AM  Valeritas Announces Poster Presentation of Preclinical h-Patch Apomorphine Study at the Global Experts Meeting on Frontiers in Alzheimers Disease & Dementia GlobeNewswire
Sep-13-19 12:29PM  A Look At Benzinga Pro's Most-Searched Tickers For September 13, 2019 Benzinga -5.52%
Sep-12-19 07:00AM  Valeritas Presents Positive CBD h-Patch Data at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit GlobeNewswire
Sep-05-19 10:39AM  GNC Holdings Inks Retail Partnership Deal to Grow in Brazil Zacks +7.34%
Sep-04-19 11:27AM  Innovation Aids Genomic Health, Merger Procedure on Track Zacks
09:24AM  Insulet (PODD) Scales 52-Week High: What's Driving the Stock? Zacks
Sep-03-19 07:00AM  Valeritas Announces Oral Presentation of Preclinical h-Patch CBD Study at the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit GlobeNewswire
Sep-02-19 11:40AM  Edited Transcript of VLRX earnings conference call or presentation 8-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-29-19 04:05PM  Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Aug-15-19 07:00AM  Clinical Trial Evaluating Delivery of Regular Human Insulin vs. Rapid Acting Insulin Delivered by Valeritas V-Go® Meets Primary A1c Endpoint GlobeNewswire
Aug-08-19 08:50PM  Valeritas Holdings, Inc. (VLRX) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:05PM  Valeritas Announces Second Quarter 2019 Financial Results GlobeNewswire
Aug-05-19 12:21PM  A Look At Benzinga Pro's Most-Searched Tickers For August 5, 2019 Benzinga
07:00AM  Preclinical Study Shows Valeritas Proprietary h-Patch Wearable Delivery Device an Effective Option for Continuous Infusion of Apomorphine GlobeNewswire
Aug-01-19 10:33AM  Will Valeritas Holdings, Inc. (VLRX) Report Negative Earnings Next Week? What You Should Know Zacks -9.41%
Jul-30-19 09:11AM  Valeritas Rallies On Positive Preclinical Data For CBD Delivery Using Wearable Device Benzinga +15.60%
07:00AM  Cannabidiol (CBD) Effectively Delivered Subcutaneously with Valeritas Proprietary h-Patch Wearable Device in Preclinical Study GlobeNewswire
Jul-25-19 09:03AM  Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas Zacks
Jul-24-19 07:15AM  Use Rising P/E Strategy to Buy 5 Winning Stocks Zacks +7.36%
Jul-22-19 07:00AM  Valeritas to Report Second Quarter 2019 Financial Results on August 8, 2019 GlobeNewswire
Jul-11-19 11:30AM  A Look At Benzinga Pro's Most-Searched Tickers For July 11, 2019 Benzinga -17.60%
Jul-08-19 07:00AM  Valeritas V-Go® Wearable Insulin Delivery Device Demonstrates Economic Advantages Compared to Multiple Daily Injection Therapy for Insulin Dependent Type 2 Diabetes Population GlobeNewswire
Jun-27-19 07:00AM  Valeritas Files Special 510(k) with FDA for Labeling Change to Include the Use of Regular Human Insulin In V-Go® Wearable Insulin Delivery Device GlobeNewswire
Jun-24-19 07:00AM  Valeritas Announces Milestone of 20 Million V-Go® Insulin Delivery Devices Sold GlobeNewswire -5.52%
Jun-13-19 01:59PM  Edited Transcript of VLRX earnings conference call or presentation 9-May-19 8:30pm GMT Thomson Reuters StreetEvents
Jun-10-19 07:00AM  Valeritas V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.3 when Intensifying from a Basal Insulin Regimen to Basal-Bolus Delivery GlobeNewswire
May-31-19 04:05PM  Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire -5.78%
May-29-19 07:00AM  Valeritas to Participate in the American Diabetes Associations 79th Scientific Sessions; Company Reiterates Second Quarter and Full-Year 2019 Revenue Guidance GlobeNewswire +37.81%
May-28-19 07:00AM  American Diabetes Association Includes Disposable Patch-Like Device, such as V-Go® from Valeritas, in the ADA Standards of Medical Care in Diabetes - 2019 GlobeNewswire +22.51%
May-22-19 07:00AM  Valeritas V-Go® Demonstrates Positive Impact in Diabetes Quality Performance Measures in an Older Adult Population GlobeNewswire -26.26%
May-17-19 07:00AM  Valeritas Announces Reverse Stock Split GlobeNewswire -16.01%
May-13-19 07:00AM  Valeritas Exhibits at Taking Control of Your Diabetes Conferences GlobeNewswire -6.74%
May-09-19 09:05PM  Valeritas Holdings, Inc. (VLRX) Reports Q1 Loss, Tops Revenue Estimates Zacks
04:05PM  Valeritas Announces First Quarter 2019 Financial Results and Updates Full Year 2019 Revenue Guidance GlobeNewswire
May-02-19 10:32AM  Will Valeritas Holdings, Inc. (VLRX) Report Negative Earnings Next Week? What You Should Know Zacks
07:00AM  Valeritas Expects First Quarter Revenue of $6.4 million GlobeNewswire
Apr-29-19 07:00AM  Valeritas to Present at Upcoming Investor Conferences GlobeNewswire
Apr-26-19 07:00AM  Valeritas V-Go® Wearable Insulin Delivery Device Demonstrates a Reduction in A1c Levels by 1.5 and Total Daily Insulin Dosage by 14% GlobeNewswire
Apr-22-19 07:00AM  Valeritas to Report First Quarter 2019 Financial Results on May 9, 2019 GlobeNewswire
Apr-08-19 07:00AM  Valeritas V-Go® Wearable Insulin Delivery Device Demonstrates 24% Reduction in Total Daily Insulin Dosage and Lower A1C Compared to Standard Insulin Treatment GlobeNewswire +9.53%
Apr-01-19 07:00AM  Valeritas partners with the American Association of Diabetes Educators (AADE) GlobeNewswire
Mar-28-19 07:00AM  Valeritas Announces V-Go® Distribution Agreement in Israel GlobeNewswire
Mar-12-19 07:00AM  Valeritas to Present at the Oppenheimer 29th Annual Healthcare Conference GlobeNewswire
Mar-11-19 02:05PM  Edited Transcript of VLRX earnings conference call or presentation 5-Mar-19 9:30pm GMT Thomson Reuters StreetEvents -6.08%
Mar-05-19 04:05PM  Valeritas Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire +8.42%
02:30PM  Valeritas Holdings, Inc. to Host Earnings Call ACCESSWIRE
Feb-28-19 04:05PM  Valeritas Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Feb-22-19 11:14AM  Healthcare Stocks Leading the Sector ACCESSWIRE
Feb-21-19 09:25AM  Tech Stocks to Watch Today ACCESSWIRE +15.04%
07:00AM  Switching to Valeritas V-Go® Wearable Insulin Delivery Device from Insulin Pen Devices for Basal-Bolus Therapy Improved Glycemic Control with Less Insulin GlobeNewswire
Feb-19-19 07:00AM  Valeritas to Present at Upcoming Investor Conferences GlobeNewswire
Feb-12-19 07:00AM  Valeritas to Report Fourth Quarter and Full Year 2018 Financial Results on March 5, 2019 GlobeNewswire
Jan-14-19 09:15AM  4 Healthcare Stocks Setting The Pace On Monday (1/14/19) ACCESSWIRE
07:00AM  Valeritas Announces V-Go® Received Preferred Status on OptumRx Formularies GlobeNewswire
Jan-03-19 08:35AM  4 Healthcare Stocks Gaining Speed on Thursday (1/3/19) ACCESSWIRE +5.59%
07:07AM  Valeritas Announces V-Go® is Preferred on Humana Part D Formularies GlobeNewswire
Dec-18-18 06:38PM  Edited Transcript of VLRX earnings conference call or presentation 9-Nov-18 1:30pm GMT Thomson Reuters StreetEvents -8.11%
08:35AM  5 Beaten-Down Medical Product Stocks to Rebound in 2019 Zacks
Nov-28-18 07:00AM  Valeritas CEO John Timberlake to Participate as a Panelist on Exploring Innovation in Diabetes Tech, at DeviceTalks West Conference GlobeNewswire +6.94%
Nov-26-18 07:00AM  Study Supports Valeritas V-Go® Can Improve Glycemic Control in Type 2 Patients When Using an Easy to Follow Physician-Driven Insulin Titration Algorithm GlobeNewswire -10.17%
Nov-15-18 08:13PM  Valeritas Announces Pricing of $36 Million Public Offering GlobeNewswire -29.20%
Nov-14-18 07:35AM  Investor Expectations to Drive Momentum within Townsquare Media, Koss, ESSA Pharma, MVC Capital, Valeritas, and Sonic Foundry Discovering Underlying Factors of Influence GlobeNewswire -20.44%
Nov-13-18 07:00AM  Valeritas Signs Exclusive Middle East Distribution Agreement with Julphar GlobeNewswire -14.39%
Nov-12-18 07:00AM  Valeritas V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical and Economic Benefits Across Established BMI Strata in Patients with Type 2 Diabetes Including Those Overweight and Obese GlobeNewswire -6.94%
Nov-09-18 07:00AM  Valeritas Reports Record Revenue for the Third Quarter 2018 GlobeNewswire -10.00%
Nov-05-18 07:00AM  Valeritas to Report Third Quarter 2018 Results November 9, 2018 GlobeNewswire
Oct-19-18 07:00AM  Valeritas Announces That V-Go® Insulin Delivery Device Has Launched in Italy GlobeNewswire
Oct-17-18 07:00AM  Valeritas Wins Fifth Consecutive Cardinal Health Supply Chain Excellence Award GlobeNewswire
Oct-16-18 08:25AM  Valeritas Holdings Revenues Grow on Acceptance of V-Go for Insulin, Analyst Report ACCESSWIRE
Oct-15-18 07:00AM  Valeritas Expects to Report Record Revenue for Third Quarter 2018 GlobeNewswire -7.35%
Oct-11-18 07:00AM  Valeritas is a Contributing Supporter of the Interactive Insulin Workshop at MEDS East Summit GlobeNewswire
Oct-10-18 07:00AM  Persistent Use of Valeritas V-Go® Wearable Insulin Delivery Device Demonstrates Significant Clinical & Economic Benefits Compared to Conventional Insulin Delivery in Patients with Type 2 Diabetes GlobeNewswire
Oct-02-18 07:00AM  Valeritas V-Go® Demonstrates Benefits Versus Multiple Daily Injections in Patients with Type 2 Diabetes GlobeNewswire
Sep-26-18 08:00AM  Valeritas Begins Medical Device Registration Process in China for Its V-Go® Wearable Insulin Delivery Device GlobeNewswire +32.00%
Aug-23-18 07:00AM  Valeritas Announces that V-Go® Insulin Delivery Device Has Launched in Australia GlobeNewswire -9.17%
Aug-21-18 07:39PM  Edited Transcript of VLRX earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents -6.43%
Aug-07-18 04:05PM  Valeritas Reports Record Second Quarter Revenue with 36% Year-over-Year Growth GlobeNewswire
02:30PM  Valeritas Holdings, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 07:00AM  Valeritas Announces V-Go® Distribution Agreement in Czech Republic and Slovakia GlobeNewswire
Aug-02-18 07:00AM  Valeritas V-Go® Wearable Insulin Delivery Device Demonstrated Improved Clinical Benefits in Patients with Uncontrolled Type 2 Diabetes Previously Treated with Multiple Daily Injections GlobeNewswire
Aug-01-18 07:00AM  Valeritas Announces that V-Go® Insulin Delivery is Now Available in New Zealand GlobeNewswire
Jul-31-18 07:31AM  Free Pre-Market Technical Recap on DENTSPLY SIRONA and Three Additional Medical Supplies Stocks ACCESSWIRE
Jul-25-18 07:00AM  Valeritas, Makers of V-Go® Insulin Delivery, is a Contributing Supporter of the Interactive Insulin Workshop at Two MEDS Conferences GlobeNewswire
Valeritas Holdings, Inc., a commercial-stage medical technology company, focuses on the development and commercialization of technologies to treat patients with Type 2 diabetes in the United States. The company offers V-Go, a wearable insulin delivery device for basal-bolus therapy. It also develops V-Go Prefill that is in the design-development stage for eliminating the device-filling process and the need for EZ fill refrigeration for patients with Type 2 diabetes; and V-Go SIM for real-time tracking information of basal and bolus dosing utilization. The company sells V-Go to third-party wholesalers and medical supply distributors. Valeritas Holdings, Inc. was founded in 2006 and is headquartered in Bridgewater, New Jersey.